Clinical trials: Pancreatic Fibrosis
Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF)
Clean Air for Rare MUcociliary Clearance dIsorders
The goal of this clinical trial is to learn whether using a high efficiency particulate air (HEPA) air purifier can improve respiratory health in children and adults with Cystic Fibrosis (CF) or Primary Ciliary Dyskinesia (PCD).
- Trial name
- CARMUCI (NCT07417267)
- Testing
- Intervention configuration - air purifiers equipped with HEPA and three other filters for efficient particle filtration
- Where
- Cyprus
- Volunteers
- 62 people
- Sponsor
- University of Cyprus
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
A CFit Study - Baseline
A great medical success is the increase in the median survival age associated with cystic fibrosis (CF). However, this success has led to a new era of research with the aim to maximise the quality of life (QoL) of the aging CF…
- Trial name
- NCT03234387
- Testing
- No intervention - only assessments.
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Portsmouth
Cystic Fibrosis, Bronchiectasis
Adherence to Airway Clearance. Novel Approaches to Improving Adherence
An airway clearance technique (ACT) is one of the core treatments for children with chronic lung diseases who are unable to clear their secretions effectively.
- Trial name
- NCT02906826
- Testing
- Video game
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Cystic Fibrosis (CF)
Antioxidant Supplements in Cystic Fibrosis Children
This randomized controlled clinical trial included 60 pediatric patients with cystic fibrosis (CF) assigned randomly into two arms; Arm 1(extra care arm):received a tailored dietary plan following Mediterranean diet to cover…
- Trial name
- NCT06875050
- Testing
- Mediterranean diet, Fat soluble vitamins supplementation, Antioxidant Supplement
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Cystic Fibrosis
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi
- Trial name
- NCT02170025
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 21 people
- Sponsor
- Bayer
Cystic Fibrosis
PTC124 for the Treatment of Cystic Fibrosis
In some patients with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein.
- Trial name
- NCT00351078
- Testing
- PTC124
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- PTC Therapeutics
Cystic Fibrosis
Perceived Impact of Art Therapy in Patients With Cystic Fibrosis and in Professional Interdisciplinary Teams Taking Care of Them.
Cystic fibrosis is so far a disease whose treatment remains essentially symptomatic care teams perceive the boundaries of a support mainly focused on drug treatments.
- Trial name
- MUCO-ART-PLUS (NCT02932657)
- Testing
- Non interventional study
- Where
- 2 sites in France
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Cystic Fibrosis, Liver Fibrosis
Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
The aim of the study is to find CF patients at risk for cystic fibrosis related liver disease (CFLD). Comparison of ultrasound by two modalities and biochemical markers with histological evaluation of liver biopsy if present.
- Trial name
- NCT02603666
- Testing
- Fibroscan
- Volunteers
- 130 people
- Sponsor
- Karolinska University Hospital
Cystic Fibrosis
Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)
This is a study to examine the effect of combining chronic oral azithromycin with inhaled tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically infected with P. aeruginosa.
- Trial name
- TEACH (NCT02677701)
- Testing
- azithromycin, inhaled tobramycin
- Where
- 39 sites in United States
- Volunteers
- 119 people
- Sponsor
- Seattle Children's Hospital
Cystic Fibrosis
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
The purpose of this study is to provide information regarding the long-term safety and pharmacodynamics of ivacaftor treatment in the pediatric population younger than 6 years of age with Cystic Fibrosis (CF) who have a CFTR…
- Trial name
- NCT01946412
- Testing
- Ivacaftor
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 33 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Hyperpolarized Imaging for New Treatments
The introduction of triple combination CFTR modulator therapy for patients with Cystic Fibrosis (CF) with at least one copy of the deltaF508 mutation is expected to provide major health benefits, but will also require novel…
- Trial name
- HyPOINT (NCT04259970)
- Testing
- Initiation of CFTR Modulator
- Where
- 4 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cystic Fibrosis
Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
To determine the pharmacokinetic profile of IV (intravenous) and PO (oral) formulations of linezolid among children with cystic fibrosis and establish a dose regimen that will be safe and effective.
- Trial name
- NCT00625703
- Testing
- Linezolid
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Texas Southwestern Medical Center
Cystic Fibrosis
Modified Release Posaconazole in Patients With Cystic Fibrosis
A prospective single center observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once daily oral formulation, can be…
- Trial name
- NCT03421366
- Testing
- Posaconazole
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Bayside Health
Cystic Fibrosis
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
Cystic fibrosis (CF) is a genetic disease characterized by mutations in CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene.
- Trial name
- NCT01288170
- Testing
- Nebcinal Tobi, Tobi Nebcinal
- Where
- 2 sites in France
- Volunteers
- 12 people
- Sponsor
- Erempharma
Cystic Fibrosis
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group, multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and triple combination with tezacaftor (TEZ…
- Trial name
- NCT02951182
- Testing
- TEZ, IVA, VX-440
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 74 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Combating Diagnostic Wandering and Impasse for Cystic Fibrosis
After cystic fibrosis (CF) neonatal screening, some children remain with a not concluded diagnosis. In France, the medical follow-up is not standardized, some of them may be lost of follow-up.
- Trial name
- NCT05654480
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Societe Francaise de la Mucoviscidose
Cystic Fibrosis
Choline Nutrition in Children With Cystic Fibrosis
Cystic fibrosis (CF) is the most common lethal, inherited disorder among Caucasians. Choline is an essential vitamin and as a methyl donor is critically needed to support the normal metabolism.
- Trial name
- NCT01070446
- Testing
- Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1
- Where
- Canada
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Cystic Fibrosis
Renal Impact of KAFTRIO in Mucoviscidose Population
The objective of this study is to describe the renal impact of Elexacaftor-Teacaftor-Ivacaftor, a triple modulator therapy of CFTR channel, in patients with cystic fibrosis.
- Trial name
- IRT-MUCO (NCT06197490)
- Testing
- Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation, Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis, Diabetes Mellitus Type I
Social Determinants in Chronic Disease in British Columbia
Anyone who practices clinical medicine will understand that socially disadvantaged children will have worse health outcomes, no matter what the underlying condition might be.
- Conditions
- Cystic Fibrosis, Diabetes Mellitus Type I, Chronic Renal Insufficiency
- Trial name
- NCT02203084
- Testing
- Social Determinants Questionnaire
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University of British Columbia
Healthy Volunteers
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.
- Trial name
- ABBV-576 DDI (NCT05530278)
- Testing
- Galicaftor, ABBV-576, Navocaftor
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.